CompletedPhase 1NCT03416036

Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge

Studying Dengue fever

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
Anna Durbin, MD, MD
Johns Hopkins Bloomberg School of Public Health
Intervention
TetraVax-DV-TV003 (TV003)(biological)
Enrollment
64 enrolled
Eligibility
18-50 years · All sexes
Timeline
20172019

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03416036 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever

← Back to all trials